Avadel Pharma says its sleep disorder drug remains under FDA review

[cafead]

via Avadel Pharmaceuticals' (AVDL.O), opens new tab sleep disorder drug for use in pediatric patients seven years and older remains under review by the U.S. Food and Drug Administration, the company said in a regulatory filing on Thursday.

article source